Is this email not displaying correctly? View it in your browser.
 
Newswise - News for Journalists
Newswise Special Wire
Tuesday, June 4, 2019

Public edition | newswise.com

Newswise Cancer Research Wire for 04-Jun-2019
 

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.


Cancer Research


Traditional chemotherapy still gold standard over new targeted therapy for HER2-positive breast cancers

Results of a phase 3 clinical trial by researchers at UCLA’s Jonsson Comprehensive Cancer Center found that women with HER2-positive breast cancer had significantly better response rates, but more severe side effects, when they were treated with tr...

– University of California, Los Angeles (UCLA), Health Sciences

Journal of Clinical Oncology.

Embargo expired on 03-Jun-2019 at 10:45 ET


Study finds DNA markers may be valuable in early detection of colorectal cancer

New studies on early detection of colorectal cancer and the quality-of-life impact of cell therapy are among several Mayo Clinic presentations at the American Society of Clinical Oncology annual meeting in Chicago.

– Mayo Clinic

American Society of Clinical Oncology annual meeting

Embargo expired on 03-Jun-2019 at 07:30 ET


Study: Genetic information can encourage women to accept preventive cancer treatment

Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by aromatase inhibitors. Nevertheless, women at high risk of breast cancer have a low acceptance of preventi...

– Mayo Clinic

American Society of Clinical Oncology Annual Meeting

Embargo expired on 03-Jun-2019 at 07:30 ET


Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center...

– Dana-Farber Cancer Institute

New England Journal of Medicine, June-2019; ASCO Annual Meeting, June-2019

Embargo expired on 02-Jun-2019 at 07:30 ET


Study finds drug therapy can delay onset of myeloma symptoms

The largest randomized trial involving smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of myeloma symptoms, according to Mayo Clinic researchers. The study was conducted by the Eastern Cooperative Oncology G...

– Mayo Clinic

American Society of Clinical Oncology Annual Meeting

Embargo expired on 02-Jun-2019 at 07:30 ET


Adding ribociclib to hormone therapy extends lives of women with most common metastatic breast cancer

A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.

– University of California, Los Angeles (UCLA), Health Sciences

New England Journal of Medicine

Embargo expired on 01-Jun-2019 at 07:30 ET


Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer

Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical t...

– University of Texas M. D. Anderson Cancer Center

New England Journal of Medicine; 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Embargo expired on 01-Jun-2019 at 07:30 ET


Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer

Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer

– Dana-Farber Cancer Institute

ASCO Annual Meeting 2019

Embargo expired on 31-May-2019 at 09:00 ET


Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients

Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas M...

– University of Texas M. D. Anderson Cancer Center

New England Journal of Medicine

Embargo expired on 29-May-2019 at 17:00 ET


Media Advisory: May 29 Johns Hopkins Telebriefing to Announce New Blood Test That Can Detect 7 Cancers From Unique Patterns in DNA Fragments

A telebriefing will announce the development by the Johns Hopkins Kimmel Cancer Center of a new “liquid biopsy” to accurately detect the presence of seven cancers using machine learning, a type of artificial intelligence. The briefing will coinci...

– Johns Hopkins Medicine

Nature

Embargo expired on 29-May-2019 at 13:00 ET


Patterns of chronic lymphocytic leukemia growth identified

In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT...

– Dana-Farber Cancer Institute

Nature; 5P01CA081534-14; 1R01CA155010-01A1; P01CA206978; U10CA180861; 1RO1HL103532-0; PIOF-2013-624924

Embargo expired on 29-May-2019 at 13:00 ET


Cervical Cancer During Pregnancy, Though Serious, is Highly Treatable According to New Research Review

“Individualized therapies are strongly recommended and the treatment decision should be made collaboratively with a multidisciplinary team consisting of obstetricians, gynecologists, oncologists, pediatricians, and psychologists,” says researcher...

– Sbarro Health Research Organization (SHRO)

Journal of Cellular Physiology


Estudio descubre marcadores del ADN potencialmente útiles para detección temprana del cáncer colorrectal

Entre varias presentaciones que Mayo Clinic hace durante la reunión anual de la Sociedad Americana de Oncología Clínica en Chicago, están estudios nuevos sobre la detección temprana del cáncer colorrectal y la repercusión de la terapia celular...

– Mayo Clinic


La información genética motiva a las mujeres a aceptar el tratamiento preventivo contra el cáncer, muestra estudio de Mayo Clinic

Los estudios muestran que la administración durante 5 años de tamoxifeno, raloxifeno e incluso de los inhibidores de la aromatasa puede reducir a la mitad el riesgo de cáncer de mama. Sin embargo, las mujeres con alto riesgo de cáncer de mama se ...

– Mayo Clinic


Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had ...

– University of Texas M. D. Anderson Cancer Center

2019 ASCO Annual Meeting


Yale Cancer Center researchers demonstrate novel drug increased survival for patients with bladder cancer.

There are no approved treatment options for patients with advanced bladder cancer after standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonst...

– Yale Cancer Center

ASCO Annual Meeting 2019


ASCO 2019: Favorable Response for Brain Cancer Patients Receiving Combination Therapy With SurVaxM

With their phase II study in patients with aggressive brain cancer now completed, the developers of the cancer immunotherapy SurVaxM report that combination therapy with the vaccine was more effective than standard therapy for nearly all patients.

– Roswell Park Comprehensive Cancer Center

ASCO Annual Meeting, Jun-2019


NUS researchers uncovers promising cancer target for liposarcoma

A study conducted by a team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has revealed a close association between liposarcoma (LPS), a type of cancer that develops from fat cell...

– National University of Singapore

Nature Communications


POLO trial for advanced pancreatic cancer: a new standard of care

Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas cancer OLaparib Ongoing) tri...

– University of Chicago Medical Center

New England Journal of Medicine


Immune cells determine how fast certain tumors grow

By examining brain tumors in mice, researchers at Washington University School of Medicine in St. Louis discovered that immune cells that should be defending the body against disease sometimes can be enticed into providing aid and comfort to tumor ce...

– Washington University in St. Louis

Neuro-Oncology, May-2019; 1-R01-CA195692-01; 1-R35-NS07211-01; UL1-TR000448


UT Southwestern develops test to predict immunotherapy response in kidney cancer

A new test to illuminate kidney cancers may identify patients who are most likely to benefit from immunotherapy.

– UT Southwestern Medical Center

Journal for ImmunoTherapy of Cancer


Immunotherapy drug found safe in treating cancer patients with HIV

The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known b...

– Fred Hutchinson Cancer Research Center

JAMA Oncology / HHSN261200800001E, ZIA BC011700, ZIA BC010885, 1U01CA154967; ASCO Annual Meeting 2019


Choosing the Right Drug to Fight Cancer

Biochemists at Université de Montreal discover a new mechanism to better predict whether an anti-cancer therapy will work.

– Universite de Montreal

Cancer Research, May 17, 2019


Immunotherapy drug improves five-year survival rate of people with advanced lung cancer

In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years — and 25% of patients whose tumor cells had a specific pr...

– University of California, Los Angeles (UCLA), Health Sciences


Radio-wave Therapy Proves Effective Against Liver Cancer Cells

A new targeted therapy using non-thermal radio waves has been shown to block the growth of liver cancer cells anywhere in the body without damaging healthy cells, according to a study conducted by scientists at Wake Forest School of Medicine, part of...

– Wake Forest Baptist Medical Center

EBioMedicine, May 31, 2019


A new way to predict complications after larynx cancer surgery

A technique that illuminates blood flow during surgery predicted which head and neck cancer patients were likely to have issues with wound healing. It could enable surgeons to make adjustments during surgery or recovery to improve outcomes.

– Michigan Medicine - University of Michigan

Annals of Surgical Oncology


Occupational Hazards Account for More than One in Ten People with Range of Lung Diseases

More than 1 in 10 people with a range of non-cancerous lung diseases may be sick as a result of inhaling vapors, gas, dust or fumes at work, according to a joint American Thoracic Society and the European Respiratory Society statement published in th...

– American Thoracic Society (ATS)

American Journal of Respiratory and Critical Care Medicine


Study: Men with Early-Stage Prostate Cancer Who Choose Active Surveillance Often Don’t Follow Monitoring Guidelines

Researchers found just 15 percent of a group of men with early-stage prostate cancer received biopsies and other tests according to active surveillance guidelines from the National Comprehensive Cancer Network.

– University of North Carolina Health Care System

ASCO Annual Meeting 2019


International Clinical Trial of New Drug for Men with Advanced Prostate Cancer Yields Strong Results

Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to tre...

– Huntsman Cancer Institute at the University of Utah

New England Journal of Medicine


Patient Groups Untested in Cancer Immunotherapy Trials Found to Also Benefit

Cancer patients previously excluded and underrepresented in immunotherapy clinical trials, such as African Americans and patients with HIV or viral hepatitis, actually benefit at the same rate as patients tested in the clinical trials, according to a...

– Georgetown Lombardi Comprehensive Cancer Center

2019 ASCO Annual Meeting


Significant “Knowledge Gap” Exists in Use of Genetic Testing to Decide Cancer Treatment

A survey conducted by Georgetown investigators found a significant knowledge and practice gap among community oncologists in the understanding and usage of genetic testing in determining patients' treatment plans and potential clinical trial outcomes...

– Georgetown Lombardi Comprehensive Cancer Center

2019 ASCO Annual Meeting


Rutgers Cancer Institute of New Jersey Physician-Scientists Present Findings on Immunotherapy and Other Clinical Research at National Meeting

Findings from Rutgers Cancer Institute of New Jersey focused on immunotherapy will be featured at the 2019 American Society of Clinical Oncology Annual Meeting being held in Chicago tomorrow through Tuesday.

– Rutgers Cancer Institute of New Jersey

2019 American Society of Clinical Oncology Annual Meeting


Heartburn drugs linked to fatal heart and kidney disease, stomach cancer

A study from researchers at Washington University School of Medicine in St. Louis and Veterans Affairs St. Louis Health Care System has linked long-term use of drugs known as proton pump inhibitors (PPIs) to fatal cases of cardiovascular disease, chr...

– Washington University in St. Louis

BMJ


Millions of women in low-and middle-income countries will need radiotherapy for cervical cancer treatment despite vaccination

A first of its kind study is reporting that millions of women in low- and middle-income countries will need life-saving radiotherapy to treat their cervical cancer, despite the growth of essential human papilloma virus (HPV) vaccination prevention pr...

– University Health Network (UHN)

The Lancet Oncology


Recovery twice as hard for survivors of childhood acute lymphoblastic leukemia

The cardiorespiratory fitness of survivors of childhood acute lymphoblastic leukemia is 22 per cent worse than that general Canadian population,and genetics might play a role, an UdeM researcher finds.

– Universite de Montreal

BMC Cancer, May-2019; Institute of Cancer Research-Canadian Institutes of Health Research


Cancer Experts and Features


New NCCN Guidelines for Children with Cancer Meet Growing Needs of Pediatric Oncology Community Worldwide

National Comprehensive Cancer Network (NCCN) debuts NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL)—comprehensive, up-to-date, evidence-based, consensus-driven guidelines for treating...

– National Comprehensive Cancer Network® (NCCN®)

Embargo expired on 30-May-2019 at 09:30 ET


Atlantic Health System Physicians Co-Author Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

Studies to be presented at the ASCO meeting are co-authored by research oncologists Eric Whitman, MD; Missak Haigentz, MD; and Angela Alistar, MD. Their ASCO studies include: two separate studies looking at TILS therapy and Keytruda for advanced mela...

– Atlantic Health System


SCCA’s Immunotherapy leaders featured at the American Society of Clinical Oncology (ASCO) annual meeting

More than 20 physicians and researchers from Seattle Cancer Care Alliance (SCCA) will present at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL May 31 – June 4, 2019.

– Seattle Cancer Care Alliance


Boise State Alumna Uses Degree to Improve Lives of Idahoans

As the health program manager of the Idaho Comprehensive Cancer Control Program, Cariou oversees statewide cancer prevention programs.

– Boise State University


Fred Hutch at ASCO: HPV vaccine uptake in U.S., immunotherapy and sarcoma, financial toxicity of cancer, health care disparities and more

...

– Fred Hutchinson Cancer Research Center


Expert Alert: Genetic testing can lead to better cancer screening, interventions

– Mayo Clinic


Cancer Announcements


Penn Receives $12 Million Grant to Study Connection Between Radiation and Immunotherapies

From understanding the genetics of cancer cells to improving cellular therapies and incorporating new methods of radiation therapy, a $12 million grant will help researchers at the Abramson Cancer Center at the University of Pennsylvania pursue the n...

– Perelman School of Medicine at the University of Pennsylvania


Henry Ford Cancer Institute Earns Full 3-Year Accreditation from National Accreditation Program for Breast Centers

The Henry Ford Cancer Institute has earned a full three-year accreditation designation by the National Accreditation Program for Breast Centers (NAPBC), a program of the American College of Surgeons. Henry Ford Hospital, Henry Ford Macomb Hospital an...

– Henry Ford Health System


AACI’s Champion for Cures Award to Recognize the Jon M. and Karen Huntsman Family

The Jon M. and Karen Huntsman family will receive the Association of American Cancer Institutes’ (AACI) 2019 Champion for Cures Award, in recognition of their significant leadership in supporting efforts to cure cancer and in inspiring others to do...

– Association of American Cancer Institutes (AACI)


NCCN and AstraZeneca Support Quality Improvements for Lung Cancer Care

The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) and AstraZeneca are collaborating to seek proposals for improving care processes for patients with unresectable stage III and stage IV non-small cell lung cancer (NSCLC)...

– National Comprehensive Cancer Network® (NCCN®)


Clinical Research Pathways Taps Emory Physician for Board of Directors

Clinical Research Pathways, a non-profit that advocates for increasing diversity in clinical research and expanding access to experimental drugs, biologics and medical devices, has added a new member to its board of directors.

– Clinical Research Pathways


Johns Hopkins Technology That Integrates Earlier Cancer Detection Into Routine Medical Care Receives Record Venture Investment

A pioneering blood test developed by Johns Hopkins researchers that incorporates earlier cancer detection into routine medical care will be developed by a new company that has raised the largest outside investment ever by a licensee of a Johns Hopkin...

– Johns Hopkins Medicine

Tips

CUSTOMIZE YOUR FAVORITES WITH "MY READING LIST"

MY CHANNELS  |  SAVED ARTICLES  |  MY SOURCES  |  MY EXPERTS

MORE CHANNELS:
JOURNAL NEWS   |  TRENDS AND TOP STORIES   |  LOCAL NEWS  |  MEDICAL and SCIENTIFIC MEETINGS

Support
 Subscribe/Unsubscribe
 Edit My Preferences
 Comments/Suggestions
 Contact Us
 
Services
 Newswise Home
 Newswise Contact Directory
 Expert Queries
 Presspass Application

More News from:

 University of Texas M. D. Anderson Cancer Center

 Seattle Cancer Care Alliance

 University of California, Los Angeles (UCLA), Health Sciences

 Washington University in St. Louis

 Michigan Medicine - University of Michigan

 American Thoracic Society (ATS)

 UT Southwestern Medical Center


Subscribe / Unsubscribe
Edit my preferences

© 2019 Newswise, Inc. All Rights Reserved.

215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417

 Contact Us